Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 7:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 365 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo eye drops Clear all
Completed Phase 4 Interventional Results available

A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin

NCT00759941
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 1% ophthalmic solution (Azopt), Placebo eye drops, Latanoprost 0.005% ophthalmic solution (Xalatan)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
35 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery

NCT00198445
View directory record Official record
Conditions
Postoperative Complications, Cataract
Interventions
Bromfenac, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

NCT02121301
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of BRM421 for Dry Eye Syndrome

NCT03066219
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
BRM421, Placebo
Drug
Lead sponsor
BRIM Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Lewiston, Maine • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

NCT03565887
View directory record Official record
Conditions
Blepharoptosis
Interventions
RVL-1201, Vehicle ophthalmic solution
Drug · Other
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
9 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
36
States / cities
Phoenix, Arizona • Garden Grove, California • Mission Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo

NCT00997035
View directory record Official record
Conditions
Corneal Ulcer, Eye Infections, Fungal
Interventions
Voriconazole, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

NCT04622345
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
VSJ-110, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

NCT01743729
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Artesia, California • Hemet, California • Lancaster, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)

NCT00429923
View directory record Official record
Conditions
Inflammation
Interventions
Difluprednate, Placebo
Drug
Lead sponsor
Sirion Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
219 participants
U.S. locations
1
States / cities
Washington, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 2, 2009 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 2 Interventional Results available

The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis

NCT05356793
View directory record Official record
Conditions
Acute Infectious Conjunctivitis (Disorder)
Interventions
SCH-1, Placebo
Drug
Lead sponsor
Sacsh
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jackson Heights, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 12, 2026, 7:06 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT02831387
View directory record Official record
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Artesia, California • Kansas City, Missouri • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 12, 2026, 7:06 PM EDT
Not listed Phase 3 Interventional

Study of EBI-005 in Dry Eye Disease (DED)

NCT02405039
View directory record Official record
Conditions
Dry Eye
Interventions
EBI-005, Placebo
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 12, 2026, 7:06 PM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

NCT01319487
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
2304 Eye Drops High Dose, 2304 Eye Drops Low Dose, Placebo Eye Drops
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Phoenix, Arizona • Fort Myers, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 1 Interventional

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

NCT04505566
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Ketorolac 0.45% ophthalmic solution, Placebo - Preservative-free artificial tears, Aqueous PGE2 and inflammatory cytokines measurements
Drug · Other
Lead sponsor
Stephen J. Kim, MD
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

NCT05136170
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Glendale, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 12, 2026, 7:06 PM EDT
Withdrawn Phase 2 Interventional

Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

NCT02511613
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Squalamine Lactate Ophthalmic Solution, 0.2%, Placebo Ophthalmic Solution, ranibizumab
Drug
Lead sponsor
Ohr Pharmaceutical Inc.
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Beverly Hills, California • Hagerstown, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

NCT01174823
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
bepotastine besilate ophthalmic solution, placebo comparator ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

NCT03414645
View directory record Official record
Conditions
Dry Eye, Graft-versus-host-disease, Ocular Discomfort
Interventions
CAM-101 10%, Vehicle Control, CAM-101 30%
Biological
Lead sponsor
Cambium Bio Limited
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Palo Alto, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

NCT00244543
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 1 Interventional

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

NCT01670266
View directory record Official record
Conditions
Ocular Hypertension (OHT), Mild Open Angle-glaucoma (OAG)
Interventions
ONO-9054, Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
3
States / cities
Costa Mesa, California • Newport Beach, California • Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

NCT04250207
View directory record Official record
Conditions
Fuchs' Endothelial Corneal Dystrophy
Interventions
K-321 Solution, Placebo Solution
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome

NCT04206020
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sun City West, Arizona • Andover, Massachusetts • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 12, 2026, 7:06 PM EDT
Completed Phase 3 Interventional

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

NCT00800267
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
53
States / cities
Anaheim, California • Sacramento, California • San Francisco, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 12, 2026, 7:06 PM EDT